Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. (June 2016)

• Record Type: Journal Article
• Authors: Hvas, Christian L.; Dige, Anders; Bendix, Mia; Wernlund, Pernille G.; Christensen, Lisbet A.; Dahlerup, Jens F.; Agnholt, Jørgen
• Is Part Of: European journal of clinical investigation. Volume 46:Number 6(2016:Jun.)
• Page Start: 555
• Page End: 563
• Publication Date: 2016-06
• Subjects: Casein glycomacropeptide -- clinical trial -- inflammatory bowel diseases -- ulcerative colitis; Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.12634
• Languages: English
• ISSNs: 0014-2972

Abstract

Abstract: Background: In ulcerative colitis (UC), dietary supplements may have anti‐inflammatory properties and improve disease course. We investigated the effects of casein glycomacropeptide (CGMP), a fraction of bovine whey protein, in active UC. Materials and methods: In a randomized open‐label intervention study, 24 patients with active UC involving 10–40 cm of the distal colon were randomized in a 2 : 1 ratio into two groups. The first group was administered their usual treatment plus a daily supplement of CGMP 30 g, and the second group was administered a dose escalation to 4800 mg oral mesalamine daily (standard treatment) for 4 weeks. Clinical, endoscopic, mucosal and circulating disease activity markers were monitored. Acceptance of and adherence to CGMP up to 8 weeks were documented. Results: After 4 weeks of treatment, 10 of 16 (63%) patients who received CGMP had an unchanged or decreased Simple Clinical Colitis Activity Index (SCCAI), which was similar to the four of eight (50%) ( P = 0·67) patients on the standard treatment. The number of patients in which SCCAI decreased by three or more did not differ between the two groups: nine of 16 (56%) in the CGMP group vs. four of eight (50%) in the standard treatment group ( P = 0·77). Changes in disease extent and severity were similar between the two groups. CGMP was well tolerated and accepted by the patients. Conclusions: The addition of CGMP as a nutritional therapy to standard treatment was safe and accepted by patients with active distal UC. The disease‐modifying effect of CGMP was similar to that of the mesalamine dose escalation.